A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

Inclusion Criteria

• •Histologically confirmed diagnosis of NSCLC and homozygous MTAP deletion detected in tumor tissue and willingness to provide archival/fresh samples at screening for central MTAP status confirmation.
• •Advanced or metastatic NSCLC not amenable to curative therapies after progression on prior therapies at the time of enrollment (based on the American Joint Committee on Cancer, Ninth Edition).
• •At least 1 measurable lesion as per RECIST v1.1.
• •Documented radiographic disease progression on or after the most recent line of treatment.
• •Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
• •Participant must be ≥ 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place) at the time of signing the ICF.
• •Capability to swallow tablets intact (without chewing or crushing).